Korea Pharma announced on the 9th that it had applied for marketing authorization for its 24-hour long-acting ADHD treatment ‘Methydur SR Cap.’

Methydur is a treatment for attention deficit hyperactivity disorder (ADHD) in children and adolescents developed by Orient Pharmaceuticals in Taiwan. The main substance contained in Methydur is methylphenidate hydrochloride, and it is available in three dosages - 22mg, 33mg, and 44mg - depending on symptoms.

In Taiwan, the drug underwent 5 Phase I trials and completed a Phase I trial on 113 children and adolescent patients, demonstrating its safety and effectiveness. The drug obtained marketing approval in Taiwan in 2018.